Birol Güvenç

780 total citations
57 papers, 445 citations indexed

About

Birol Güvenç is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Birol Güvenç has authored 57 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 24 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Birol Güvenç's work include Hemoglobinopathies and Related Disorders (13 papers), Acute Myeloid Leukemia Research (7 papers) and Iron Metabolism and Disorders (7 papers). Birol Güvenç is often cited by papers focused on Hemoglobinopathies and Related Disorders (13 papers), Acute Myeloid Leukemia Research (7 papers) and Iron Metabolism and Disorders (7 papers). Birol Güvenç collaborates with scholars based in Türkiye, United States and France. Birol Güvenç's co-authors include Carlo Brugnara, Isabel Bize, Emel Gürkan, Fikri Başlamıslı, Melek Ergin, Berna Bozkurt Duman, Berksoy Şahin, Abdullah Canataroğlu, Sevcan Tuğ Bozdoğan and Hacer Bozdemir and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and American Journal of Physiology-Cell Physiology.

In The Last Decade

Birol Güvenç

38 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Birol Güvenç Türkiye 13 173 169 105 79 47 57 445
Μαρία Σαμαρά Greece 13 183 1.1× 154 0.9× 155 1.5× 51 0.6× 60 1.3× 37 544
Marta S. Gallego Argentina 15 98 0.6× 317 1.9× 228 2.2× 40 0.5× 95 2.0× 43 644
Milena Batchvarova United States 9 244 1.4× 228 1.3× 105 1.0× 145 1.8× 32 0.7× 15 496
F. M. Fink Austria 11 60 0.3× 190 1.1× 125 1.2× 28 0.4× 46 1.0× 21 439
Paola Orsini Italy 18 121 0.7× 182 1.1× 236 2.2× 27 0.3× 12 0.3× 38 803
Yingqi Shao China 12 134 0.8× 256 1.5× 91 0.9× 42 0.5× 12 0.3× 53 492
Ariane Lapierre France 9 56 0.3× 85 0.5× 113 1.1× 41 0.5× 17 0.4× 26 344
Guopan Yu China 14 199 1.2× 428 2.5× 214 2.0× 40 0.5× 80 1.7× 69 763
Francisco José Ortuño Spain 13 173 1.0× 314 1.9× 117 1.1× 23 0.3× 17 0.4× 47 570
Eva Simmons-OʼBrien United States 6 48 0.3× 112 0.7× 50 0.5× 66 0.8× 22 0.5× 7 429

Countries citing papers authored by Birol Güvenç

Since Specialization
Citations

This map shows the geographic impact of Birol Güvenç's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birol Güvenç with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birol Güvenç more than expected).

Fields of papers citing papers by Birol Güvenç

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birol Güvenç. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birol Güvenç. The network helps show where Birol Güvenç may publish in the future.

Co-authorship network of co-authors of Birol Güvenç

This figure shows the co-authorship network connecting the top 25 collaborators of Birol Güvenç. A scholar is included among the top collaborators of Birol Güvenç based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birol Güvenç. Birol Güvenç is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Güvenç, Birol, et al.. (2025). AML-225: A Case of Achalasia After Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 25. S410–S410.
2.
Güvenç, Birol, et al.. (2025). REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT. Hematology Transfusion and Cell Therapy. 47. 103912–103912.
3.
Güvenç, Birol, et al.. (2024). A Rare Intersection: Case Study on Sickle-Cell Thalassemia and Lymphoma. Hematology Transfusion and Cell Therapy. 46. 10–10.
4.
Güvenç, Birol, et al.. (2024). SYSTEMIC NODULAR SCLEROSING HODGKIN LYMPHOMA WITH UNUSUAL HEPATIC AND GASTRIC INVOLVEMENT: A CASE REPORT. Hematology Transfusion and Cell Therapy. 46. S76–S77.
5.
Güvenç, Birol, et al.. (2024). MYCOSIS FUNGOIDES PROGRESSING TO PERIPHERAL T-CELL LYMPHOMA AND THE POTENTIAL ROLE OF ROMIDEPSIN THERAPY. Hematology Transfusion and Cell Therapy. 46. S73–S74.
6.
Güvenç, Birol, et al.. (2024). MPN-233 The Intersection of Thalassemia Minor and Chronic Myeloproliferative Disorders: Clinical and Laboratory Implications. Clinical Lymphoma Myeloma & Leukemia. 24. S423–S423.
7.
Yıldızdaş, Dinçer, et al.. (2024). Therapeutic plasma exchange in critically ill children: 18-year experience of a tertiary care paediatric intensive care unit. Australian Critical Care. 37(4). 592–599. 3 indexed citations
8.
Güvenç, Birol, et al.. (2024). PLEURAL EFFUSION DEVELOPING AS A CONSEQUENCE OF G-CSF ADMINISTRATION IN A PATIENT UNDERGOING AML TREATMENT. Hematology Transfusion and Cell Therapy. 46. S41–S42.
9.
10.
Arat, Mutlu, Yahya Büyükaşık, Seçkin Çağırgan, et al.. (2023). Unmet clinical needs and challenges in the management of acute leukemia in Turkey: a modified Delphi study. Future Oncology. 19(14). 975–982.
11.
Miyamoto, Toshihiro, David Sanford, Ciprian Tomuleasa, et al.. (2022). Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy *. Leukemia & lymphoma. 63(4). 928–938. 8 indexed citations
12.
13.
Saydam, Güray, Rıdvan Ali, Ahmet Muzaffer Demir, et al.. (2022). The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. PubMed. 11(1). IJH38–IJH38. 11 indexed citations
14.
Güvenç, Birol, et al.. (2021). LENALIDOMIDE ASSOCIATED İMMUNE THROMBOCYTOPENIA: A CASE REPORT. Hematology Transfusion and Cell Therapy. 43. S43–S44.
15.
Büyükaşık, Yahya, İbrahim C. Haznedaroğlu, Gülsüm Özet, et al.. (2017). The Modelled Effectiveness of Ruxolitinib on Survival in Polycythemia Patients with Hydroxyurea Resistance/Intolerance in Turkey. Value in Health. 20(9). A545–A545. 1 indexed citations
16.
Candevir, Aslıhan, et al.. (2015). Hepatitis B, Hepatitis C, Human immunodeficiency virus and syphilis frequency among blood donors: A single center study. Transfusion and Apheresis Science. 53(3). 308–314. 14 indexed citations
17.
Güvenç, Birol, et al.. (2012). β-Globin chain abnormalities with coexisting α-thalassemia mutations. Archives of Medical Science. 4(4). 644–649. 9 indexed citations
18.
Uz, Burak, et al.. (2011). The Efficacy and Safety of Hypertonic Citrate as Catheter-Locking Solution in Hematopoietic Stem Cell Transplant Recipients. 23(1). 48–53. 1 indexed citations
19.
Aslan, Kezban, et al.. (2007). The effect of antiepileptic drugs on vitamin B12 metabolism. International Journal of Laboratory Hematology. 30(1). 26–35. 13 indexed citations
20.
Güvenç, Birol, Abdullah Canataroğlu, Yüksel Gümürdülü, Derya Gümürdülü, & Semra Paydaş. (2001). Multiple myeloma with skin involvement. Journal of the European Academy of Dermatology and Venereology. 15(4). 328–329. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Μαρία Σαμαρά Breakdown of academic impact, for papers by Marta S. Gallego Breakdown of academic impact, for papers by Milena Batchvarova Breakdown of academic impact, for papers by F. M. Fink Breakdown of academic impact, for papers by Paola Orsini Breakdown of academic impact, for papers by Yingqi Shao Breakdown of academic impact, for papers by Ariane Lapierre Breakdown of academic impact, for papers by Guopan Yu Breakdown of academic impact, for papers by Francisco José Ortuño Breakdown of academic impact, for papers by Eva Simmons-OʼBrien
Rankless by CCL
2026